Jungaberle H
MIND Foundation, Berlin, Germany.
ArticlePsilocybin
Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression: 6- and 12-Month Naturalistic Follow-Up of a Phase 2b Trial.
ArticlePsilocybin
Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial.
ArticlePsychedelics
Psychedelics: The pathway to implementation in the European healthcare systems.
ArticlePsychedelics
Common factors in altered states: Understanding psychedelic therapy through the lens of Grawe's general change mechanisms.
ArticlePsilocybin
Compassionate use of psilocybin for treatment-resistant depression in Germany.
ArticlePsychedelics
Key competencies for psychedelic treatment in real-world mental health care settings.
ArticlePsychedelics
Decreased CO<sub>2</sub> saturation during circular breathwork supports emergence of altered states of consciousness.
ArticlePsilocybin
[Acceptance of psilocybin-assisted therapy in German-speaking countries].
ArticlePsilocybin
Psilocybin as a Disease-Modifying Drug—A Salutogenic Approach in Psychiatry.
ArticlePsychedelics
Measuring psychotherapeutic processes in the context of psychedelic experiences: Validation of the General Change Mechanisms Questionnaire (GCMQ).
ArticlePsilocybin
Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) - Rationale and study design.
ArticlePsilocybin
The Potential Role of Psychedelic Drugs in Mental Health Care of the Future.
ArticlePsilocybin
Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance.
ArticlePsilocybin
Microdosing psychedelics: Motivations, subjective effects and harm reduction.
ArticlePsilocybin
Psychedelic Microdosing: A Subreddit Analysis.
ArticlePsilocybin
Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review.
ArticlePsilocybin